RE:RE:RE:Tilray history will repeat in JulyTilray is controlling expenses, they are also increasing net revenue faster than CURA. Where TLRY reported 30% growth CURA only reported 3%
Tilray is not bound to Canada with sakes to over 20 other countries and medical cannabis facilities in Germany.
As per recent press release they are preparing to raise the funds necessary to purchase another company to position themselves better for entry into the US.
Tilray has already suffered the slings and arrows of the market with their shares trading under book value. The company survived the beatings and is proving out to be a major player that will be one of few cannabis companies.
The upcoming year end report can be expected to show something just under 1 Billion USD in net sales and another step towards a profitable report.
The company has yet to turn profitable however once it does the shares will no longer be trading at such a discount to book.